Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Secures $486 Million From U.S. Government for Coronavirus Antibody Cocktail

By Brian Orelli, PhD – Oct 9, 2020 at 7:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company plans to start phase 3 studies shortly.

AstraZeneca (AZN -0.15%) has secured $486 million from the U.S. government's Biomedical Advanced Research and Development Authority to support the development of AZD7442, an antibody cocktail for the treatment and prevention of COVID-19.

For its support, BARDA will get up to 100,000 doses of the drug and has the option to purchase up to 1 million additional doses of the treatment in 2021. The company didn't disclose the value of the potential million-dose contract.

AZD7442 is a cocktail of two long-acting antibodies designed to last for six to 12 months, making it especially useful for long-term prevention of COVID-19.

AstraZeneca plans to start two phase 3 clinical trials in the next few weeks. One study will test the ability of AZD7442 to prevent infection of the coronavirus that causes COVID-19 for up to 12 months in approximately 5,000 participants. The second study will test the antibodies in 1,100 people who have been exposed to the virus in an attempt to prevent symptoms from developing.

A nurse administering an injection to a patient.

Image source: Getty Images.

The company also plans to test AZD7442 as a treatment for COVID-19, but it's behind Eli Lilly (LLY -0.93%) and Regeneron Pharmaceuticals (REGN -1.49%), which have both already asked for emergency use authorizations for their respective coronavirus antibodies.

Vaccines will probably be more widely used given the relatively higher costs of manufacturing antibodies compared to the typical vaccine. Nevertheless, AZD7442 could be an option for patients with compromised immune systems. It could also see broader adoption if leading vaccines aren't able to protect people from COVID-19 for very long (or at all).

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.11 (-0.15%) $0.10
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$362.37 (-0.93%) $-3.40
Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
$730.41 (-1.49%) $-11.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.